Ediger Marwood N, Olson Byron P, Maynard John D
VeraLight, Inc., Albuquerque, New Mexico87106, USA.
J Diabetes Sci Technol. 2009 Jul 1;3(4):776-80. doi: 10.1177/193229680900300426.
Advanced glycation end products (AGEs) are implicated in the complications of diabetes. Advanced glycation end products also accumulate in the skin and are sensitive biomarkers for the risk of developing diabetes and related complications. Some AGEs fluoresce and can be measured noninvasively by optical spectroscopy.
Noninvasive screening for diabetes has been evaluated in an 18-site study involving a cohort of 2793 subjects meeting American Diabetes Association-based screening criteria. Subjects were measured with a specialized skin fluorimeter and also received traditional blood glucose and glycated hemoglobin tests.
Retrospective results indicated that the noninvasive technology measuring dermal fluorescence is more sensitive at detecting abnormal glucose tolerance than either fasting plasma glucose or glycated hemoglobin A1C.
These results suggest that noninvasive measurement of dermal fluorescence may be an effective tool to identify individuals at risk for diabetes and its complications. The noninvasive technology yields immediate results, and since measuring dermal fluorescence requires no blood draws or patient fasting, the instrument may be well suited for opportunistic screening.
晚期糖基化终末产物（AGEs）与糖尿病并发症有关。晚期糖基化终末产物也会在皮肤中积聚，是发生糖尿病及相关并发症风险的敏感生物标志物。一些AGEs会发出荧光，可通过光谱学进行无创测量。
在一项涉及2793名符合美国糖尿病协会筛查标准的受试者队列的18个地点的研究中，对糖尿病的无创筛查进行了评估。用专门的皮肤荧光计对受试者进行测量，并让他们接受传统的血糖和糖化血红蛋白检测。
回顾性结果表明，测量皮肤荧光的无创技术在检测糖耐量异常方面比空腹血糖或糖化血红蛋白A1C更敏感。
这些结果表明，皮肤荧光的无创测量可能是识别糖尿病及其并发症风险个体有效工具。这种无创技术能立即得出结果，而且由于测量皮肤荧光无需抽血或患者空腹，该仪器可能非常适合机会性筛查。
